Polylactic acid for visualizing the vitreous body during vitrectomy

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 7, 2007, Pages 3277-3282

  Yamashita, Toshifumi ^a   Sakamoto, Taiji ^a   Yamakiri, Keita ^a   Miura, Muneki ^b   Enaida, Hiroshi ^b   Ueno, Akifumi ^b   Atsumi, Ikuyo ^c   Matsuhisa, Keucht ^c   Sakamoto, Yuji ^c   Kida, Tetsuo ^c   Ishibashi, Tatsuro ^b  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c SENJU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

POLYLACTIC ACID; CONTRAST MEDIUM; DIAGNOSTIC AGENT; LACTIC ACID; POLYMER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; ARTICLE; CATARACT; CONTROLLED STUDY; ELECTRORETINOGRAM; EYE INFLAMMATION; HISTOLOGY; INTRAOCULAR PRESSURE; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL; RABBIT; RETINA; RETINA HEMORRHAGE; SPIKE; SUSPENSION; VITRECTOMY; VITREOUS BODY; ANIMAL; ANTERIOR EYE SEGMENT; DRUG EFFECT; ELECTRORETINOGRAPHY; INJECTION; MACACA; PATHOLOGY;

ANIMALS; ANTERIOR EYE SEGMENT; CONTRAST MEDIA; ELECTRORETINOGRAPHY; INJECTIONS; INTRAOCULAR PRESSURE; LACTIC ACID; MACACA FASCICULARIS; MALE; POLYMERS; RABBITS; RETINA; SUSPENSIONS; VITRECTOMY; VITREOUS BODY;

EID: 34548075340     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-1020     Document Type: Article

References (15)

1. Smiddy WE, Flynn HW Jr. Vitrectomy in the management of dia-betic retinopathy. Surv Ophthalmol. 1999;43:491-507.
2. Peyman GA, Cheema R, Conway MD, et al. Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina. 2000;20:554-555.
3. Sakamoto T, Miyazaki M, Hisatomi T, et al. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefes Arch Clin Exp Ophthalmol. 2002;240:423-429.
4. Yamakiri K, Sakamoto T, Noda Y, et al. Reduced incidence of intraoperative complications in a multicenter controlled clinical trial of triamcinolone in vitrectomy. Ophthalmology. 2007;114:289-296.
5. Tognetto D, Zenoni S, Sanguinetti G, Haritoglou C, Ravalico G. Staining of the internal limiting membrane with intravitreal triamcinolone acetonide. Retina. 2005;25:462-467.
6. Shah GK, Rosenblatt BJ, Blinder KJ, Grand MG, Smith M. Triamcinolone-assisted internal limiting membrane peeling. Retina. 2005;25:972-975.
7. Mochizuki Y, Hata Y, Enaida H, et al. Evaluating adjunctive surgical procedures during vitrectomy for diabetic macular edema. Retina. 2006;26:143-148.
8. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2003;136:791-796.
9. Simamora P, Chern W. Poly-Mactic acid: an overview. J Drugs Dermatol. 2006;5:436-440.
10. Athanasiou KA, Agrawal CM, Barber FA, et al. Orthopaedic applications for PLA-PGA biodegradable polymers. Arthroscopy. 1998;14:726-737.
11. Ito S, Sakamoto T, Tahara Y, et al. The effect of tranilast on experimental proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1999;237:691-696.
12. Vleggaar D, Bauer U. Facial enhancement and the European experience with Sculptra (poly-L-lactic acid). J Drugs Dermatol. 2004;3:542-547.
13. Okada H. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev. 1997;28:43-70.
14. Hashizoe M, Ogura Y, Kimura H, et al. Scleral plug of biodegradable polymers for controlled drug release in the vitreous. Arch Ophthalmol. 1994;112:1380-1384.
15. Ogura Y, Kimura H. Biodegradable polymer microspheres for targeted drug delivery to the retinal pigment epithelium. Surv Ophthalmol. 1995;39(suppl 1):S17-S24.